Question
Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
Direct answer
Vertex Pharmaceuticals disclosed Phase IIb AMPLIFIED trial results demonstrating that inaxaplin achieved a 42.7% reduction in UACR for APOL1-mediated kidney disease patients with modest proteinuria. In patients with comorbid type II diabetes, UACR reduction was 17.3%.
With enrollment in the Phase II/III AMPLITUDE pivotal trial now closed, clinical focus shifts to final registrational endpoints for the first potential APOL1-targeted therapy.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-24
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/vertex-reports-phase-iib-data-for-inaxaplin-with-42-7-proteinuria-drop-in-amkd-cfb5eb
Vertex Pharmaceuticals disclosed Phase IIb AMPLIFIED trial results demonstrating that inaxaplin achieved a 42.7% reduction in UACR for APOL1-mediated kidney disease patients with modest proteinuria. In patients with comorbid type II diabetes, UACR reduction was 17.3%.
With enrollment in the Phase II/III AMPLITUDE pivotal trial now closed, clinical focus shifts to final registrational endpoints for the first potential APOL1-targeted therapy.
Transmission
01 · Catalyst
Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
02 · Mechanism
Demonstrated 42.7% UACR reduction de-risks pivotal Phase II/III AMPLITUDE study approval, securing VRTX's non-CF revenue diversification pipeline.
No verifiable public source recorded for this card.